Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDB 401 B

Drug Profile

MDB 401 B

Alternative Names: Attenuated Salmonella typhimurium containing human IL-2; MDB401B; Salmonella-IL2; Saltikva®

Latest Information Update: 29 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Salspera; Sunshine Lake Pharma
  • Developer Salspera
  • Class Antineoplastics; Bacteria; Gene therapies; Immunotherapies
  • Mechanism of Action Interleukin-2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Gastrointestinal cancer; Solid tumours

Most Recent Events

  • 05 Jan 2023 Efficacy and adverse events data from a phase II trial in Pancreatic cancer released by Salspera
  • 05 Jan 2023 Salspera plans a phase III trial for Pancreatic cancer at unknown location
  • 26 Dec 2022 Phase II development for Pancreatic cancer is still ongoing in Canada (Salspera pipeline, December 2022) (NCT04589234)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top